FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086751489> ?p ?o ?g. }

• W2086751489 endingPage "605" @default.
• W2086751489 startingPage "601" @default.
• W2086751489 abstract "Despite progress in the understanding of leukemia pathophysiology, the treatment of acute myeloid leukemia (AML) remains challenging. In patients with refractory or relapsed (R/R) AML, the prognosis is still poor and this group is targeted for new drug development. We reviewed the outcome of 47 patients, with R/R AML after at least one course of intensive chemotherapy, treated with 5-azacytidine in three different French institutions. The overall response rate was 38% including complete remission in 21%, partial remission in 11%, and hematological improvement in 6% of cases. Median time to relapse was 6 (range, 1–39) months. Median overall survival was 9 months (not reached by responders vs. 4.5 months for nonresponders patients, P = 0.0001). Univariate analysis identified the absence of peripheral blood blasts and <20% bone marrow blasts as prognostic factors for both overall response and survival, but not age, ECOG/PS, type of AML, cytogenetic, status of the disease, number of previous lines of therapy, previous hematological stem cell transplantation, or white blood cells count. Bone marrow blasts percentage <20% was the only independent prognostic factor identified by multivariate analysis for overall response (P = 0.0013) and survival (P = 0.0324). Six patients in remission could proceed to an allogenic hematological stem cell transplantation. The drug-related grade 3/4 adverse events were hematopoietic toxicities (38%) and infection (32%). In conclusion, this study suggests that a salvage therapy with 5-azacytidine is an interesting option for patients with R/R AML after intensive chemotherapy. Prospective randomized studies are needed to demonstrate a superiority of this approach over others strategies. Am. J. Hematol. 88:601–605, 2013. © 2013 Wiley Periodicals, Inc." @default.
• W2086751489 created "2016-06-24" @default.
• W2086751489 creator A5023091403 @default.
• W2086751489 creator A5027542373 @default.
• W2086751489 creator A5033731496 @default.
• W2086751489 creator A5035494468 @default.
• W2086751489 creator A5071217362 @default.
• W2086751489 creator A5072922858 @default.
• W2086751489 creator A5074957081 @default.
• W2086751489 creator A5077081397 @default.
• W2086751489 creator A5079476625 @default.
• W2086751489 creator A5086300417 @default.
• W2086751489 date "2013-05-30" @default.
• W2086751489 modified "2023-10-13" @default.
• W2086751489 title "5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy" @default.
• W2086751489 cites W1965832312 @default.
• W2086751489 cites W1973392550 @default.
• W2086751489 cites W1976288691 @default.
• W2086751489 cites W1995697319 @default.
• W2086751489 cites W1996917824 @default.
• W2086751489 cites W2007042448 @default.
• W2086751489 cites W2028627376 @default.
• W2086751489 cites W2034612532 @default.
• W2086751489 cites W2050519979 @default.
• W2086751489 cites W2097192169 @default.
• W2086751489 cites W2105961905 @default.
• W2086751489 cites W2106084333 @default.
• W2086751489 cites W2118771330 @default.
• W2086751489 cites W2126217509 @default.
• W2086751489 cites W2126572589 @default.
• W2086751489 cites W2129510594 @default.
• W2086751489 cites W2149058047 @default.
• W2086751489 cites W2157287007 @default.
• W2086751489 cites W2159507916 @default.
• W2086751489 cites W4376595466 @default.
• W2086751489 doi "https://doi.org/10.1002/ajh.23464" @default.
• W2086751489 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23619977" @default.
• W2086751489 hasPublicationYear "2013" @default.
• W2086751489 type Work @default.
• W2086751489 sameAs 2086751489 @default.
• W2086751489 citedByCount "45" @default.
• W2086751489 countsByYear W20867514892013 @default.
• W2086751489 countsByYear W20867514892014 @default.
• W2086751489 countsByYear W20867514892015 @default.
• W2086751489 countsByYear W20867514892016 @default.
• W2086751489 countsByYear W20867514892017 @default.
• W2086751489 countsByYear W20867514892018 @default.
• W2086751489 countsByYear W20867514892019 @default.
• W2086751489 countsByYear W20867514892020 @default.
• W2086751489 countsByYear W20867514892021 @default.
• W2086751489 countsByYear W20867514892022 @default.
• W2086751489 countsByYear W20867514892023 @default.
• W2086751489 crossrefType "journal-article" @default.
• W2086751489 hasAuthorship W2086751489A5023091403 @default.
• W2086751489 hasAuthorship W2086751489A5027542373 @default.
• W2086751489 hasAuthorship W2086751489A5033731496 @default.
• W2086751489 hasAuthorship W2086751489A5035494468 @default.
• W2086751489 hasAuthorship W2086751489A5071217362 @default.
• W2086751489 hasAuthorship W2086751489A5072922858 @default.
• W2086751489 hasAuthorship W2086751489A5074957081 @default.
• W2086751489 hasAuthorship W2086751489A5077081397 @default.
• W2086751489 hasAuthorship W2086751489A5079476625 @default.
• W2086751489 hasAuthorship W2086751489A5086300417 @default.
• W2086751489 hasBestOaLocation W20867514891 @default.
• W2086751489 hasConcept C121332964 @default.
• W2086751489 hasConcept C126322002 @default.
• W2086751489 hasConcept C142424586 @default.
• W2086751489 hasConcept C143998085 @default.
• W2086751489 hasConcept C144301174 @default.
• W2086751489 hasConcept C2776694085 @default.
• W2086751489 hasConcept C2777408962 @default.
• W2086751489 hasConcept C2778461978 @default.
• W2086751489 hasConcept C2778729363 @default.
• W2086751489 hasConcept C2780007613 @default.
• W2086751489 hasConcept C2911091166 @default.
• W2086751489 hasConcept C38180746 @default.
• W2086751489 hasConcept C71924100 @default.
• W2086751489 hasConcept C87355193 @default.
• W2086751489 hasConcept C90924648 @default.
• W2086751489 hasConceptScore W2086751489C121332964 @default.
• W2086751489 hasConceptScore W2086751489C126322002 @default.
• W2086751489 hasConceptScore W2086751489C142424586 @default.
• W2086751489 hasConceptScore W2086751489C143998085 @default.
• W2086751489 hasConceptScore W2086751489C144301174 @default.
• W2086751489 hasConceptScore W2086751489C2776694085 @default.
• W2086751489 hasConceptScore W2086751489C2777408962 @default.
• W2086751489 hasConceptScore W2086751489C2778461978 @default.
• W2086751489 hasConceptScore W2086751489C2778729363 @default.
• W2086751489 hasConceptScore W2086751489C2780007613 @default.
• W2086751489 hasConceptScore W2086751489C2911091166 @default.
• W2086751489 hasConceptScore W2086751489C38180746 @default.
• W2086751489 hasConceptScore W2086751489C71924100 @default.
• W2086751489 hasConceptScore W2086751489C87355193 @default.
• W2086751489 hasConceptScore W2086751489C90924648 @default.
• W2086751489 hasIssue "7" @default.
• W2086751489 hasLocation W20867514891 @default.
• W2086751489 hasLocation W20867514892 @default.
• W2086751489 hasOpenAccess W2086751489 @default.

• next